1. THU0172 Symptomatic Subcutaneous Anti-Tumor Necrosis Factor-Treated Rheumatoid Arthritis Patients Respond to Golimumab following an Active Switch. (10th June 2014) Authors: Huffstutter, J.E.; Kafka, S.; Brent, L.H.; Matucci-Cerinic, M.; Tang, K.L.; Wang, J.; Decktor, D.D.; Chevrier, M.; Sprabery, T.; DeHoratius, R. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 240 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0388 Combining RNA-SEQ and Machine Learning to Classify an Sle-Specific Gene Signature and in Vitro Responses to IFN-I Pathway Inhibition. (9th June 2015) Authors: Cesaroni, M.; Jordan, J.; Schreiter, J.; Chevrier, M.; Shao, W.-H.; Hilliard, B.; Cohen, P.; Caricchio, R.; Benson, J. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 337 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0303 Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study. (12th June 2018) Authors: van Vollenhoven, R.; Hahn, B.H.; Tsokos, G.C.; Wagner, C.; Lipsky, P.; Hsu, B.; Chevrier, M.; Gordon, R.; Triebel, M.; Rose, S. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 689 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP0161 ASSOCIATION OF BASELINE CYTOTOXIC GENE EXPRESSION WITH USTEKINUMAB RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUS. (2nd June 2020) Authors: Seridi, L.; Cesaroni, M.; Loza, M. J.; Schreiter, J.; Sweet, K.; Orlovsky, Y.; Baribaud, I.; Orillion, A.; Lipsky, P.; Vollenhoven, R. V.; Hahn, B. H.; Tsokos, G.; Chevrier, M.; Rose, S.; Baribaud, F.; Jordan, J. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FRI0339 Sledai-2k responder index-50 is effective in demonstrating partial response in a phase 2, randomised placebo-controlled study of ustekinumab in patients with active systemic lupus erythematosus. (12th June 2018) Authors: Touma, Z.; Urowitz, M.B.; Gladman, D.D.; Wagner, C.; Hsu, B.; Chevrier, M.; Rose, S.; Zhou, B.; Gordon, R. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR). (1st December 2017) Authors: Blauvelt, A.; Ferris, L.K.; Yamauchi, P.S.; Qureshi, A.; Leonardi, C.L.; Farahi, K.; Fakharzadeh, S.; Hsu, M.‐C.; Li, S.; Chevrier, M.; Smith, K.; Goyal, K.; Chen, Y.; Muñoz‐Elías, E.J.; Callis Duffin, K. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1552 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease‐based registry (PSOLAR). (1st July 2014) Authors: Kimball, A.B.; Leonardi, C.; Stahle, M.; Gulliver, W.; Chevrier, M.; Fakharzadeh, S.; Goyal, K.; Calabro, S.; Langholff, W.; Menter, A. Journal: British journal of dermatology Issue: Volume 171:Number 1(2014:Jul.) Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Annealing effect on the electrical proprieties of IF(CN2)2-meta based OTFTs: Thermal behavior and modeling of charge transport. (November 2018) Authors: Arfaoui, N.; Mahdouani, M.; Bouhadda, I.; Poriel, C.; Bourguiga, R.; Jacques, E.; Chevrier, M.; Bebiche, S. Journal: Superlattices and microstructures Issue: Volume 123(2018) Page Start: 286 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR). (16th November 2017) Authors: Blauvelt, A.; Ferris, L.K.; Yamauchi, P.S.; Qureshi, A.; Leonardi, C.L.; Farahi, K.; Fakharzadeh, S.; Hsu, M.‐C.; Li, S.; Chevrier, M.; Smith, K.; Goyal, K.; Chen, Y.; Muñoz‐Elías, E.J.; Callis Duffin, K. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1552 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease‐based registry (PSOLAR)3. (16th July 2014) Authors: Kimball, A.B.; Leonardi, C.; Stahle, M.; Gulliver, W.; Chevrier, M.; Fakharzadeh, S.; Goyal, K.; Calabro, S.; Langholff, W.; Menter, A.; the PSOLAR Steering Committee Journal: British journal of dermatology Issue: Volume 171:Number 1(2014:Jul.) Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗